CAMP4 Therapeutics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAMP research report →
Range $6 – $15
Price Chart
About the company
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
- CEO
- Joshua Mandel-Brehm
- IPO
- 2024
- Employees
- 48
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on CAMP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $237.84M
- P/E
- -1.85
- PEG
- -0.10
- P/S
- 44.71
- P/B
- 2.79
- EV/EBITDA
- -1.39
- Div Yield
- 0.00%
- Gross Margin
- 80.39%
- Op Margin
- -1001.05%
- Net Margin
- -2276.33%
- ROE
- -261.83%
- ROIC
- -46.00%
Latest fiscal year · YoY change
- Revenue
- $3.50M+436.5%
- Gross Profit
- $1.86M+185.1%
- Op Income
- $-52,061,000
- Net Income
- $-80,403,000-55.2%
- EPS
- $-2.65+0.4%
- OCF Growth
- +35.1%
- FCF Growth
- +35.2%
- 52W High
- $7.75
- 52W Low
- $2.90
- 50D MA
- $3.82
- 200D MA
- $4.21
- Beta
- 0.21
- RSI (14)
- 48
- Avg Volume
- 238.88K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CalAmp finished fiscal 2018 with record quarterly revenue, stronger cash flow, and growing SaaS momentum, while continuing a strategic shift away from legacy LoJack SVR toward telematics and subscriptions.· April 26, 2018
- Q4 revenue hit a record $94.4 million, up 10% year over year; full-year revenue was $365.9 million, up about 4% reported and 9% excluding the exited Satellite business.
- Free cash flow was $58.6 million in fiscal 2018, up 228% year over year, helped by operations and a $28.3 million legal settlement gain.
- Software and Subscription Services revenue was $16.1 million in Q4, with deferred revenue rising to $34.5 million, up 28% year over year.
- LoJack is being repositioned toward telematics-led recurring revenue, but management said SVR-only sales will likely keep declining in the near term.
- Q1 fiscal 2019 guidance called for revenue of $91 million to $95 million and adjusted EBITDA of $12 million to $14 million.
Revenue: Q4 consolidated revenue was $94.4 million, up 10% year over year; fiscal 2018 revenue was $365.9 million, up approximately 4% year over year, or up 9% excluding Satellite revenue. Gross profit was $38.4 million in Q4, up 7% year over year, with gross margin around 41% versus 42% last year; full-year gross profit was $151 million, up 5%, and gross margin was about 41%. GAAP net loss in Q4 was $4.8 million, or $0.13 per diluted share, versus a $4.2 million loss, or $0.12 per share, a year ago; full-year GAAP net income was $16.6 million, or $0.46 per diluted share, versus a $7.9 million loss, or $0.22 per share, last year. Non-GAAP net income was $10.9 million, or $0.30 per diluted share, in Q4 versus $9.9 million, or $0.28 per share, last year; full-year non-GAAP net income was $42.2 million, or $1.17 per share, versus $38.6 million, or $1.06 per share. Adjusted EBITDA was $13.1 million in Q4 at a 14% margin; full-year adjusted EBITDA was $52.4 million at a 14% margin. Free cash flow was $58.6 million for fiscal 2018, up 228% year over year, and cash plus marketable securities were $156 million versus debt of $154.3 million at year-end. For Q1 fiscal 2019, management expects revenue of $91 million to $95 million, GAAP and non-GAAP EPS of $0.26 to $0.32, and adjusted EBITDA of $12 million to $14 million.
Michael Burdiek framed fiscal 2018 as a year of “transformative” milestones, emphasizing record revenue, stronger cash generation, and progress in realigning the sales organization around SaaS and telematics. He highlighted major customer wins, growth at Caterpillar, the LoJack pivot toward telematics-enabled services, and new opportunities to monetize the installed base through partnerships. His tone was constructive and optimistic, but he also acknowledged near-term pressure from the LoJack transition and from customer hesitation around LTE upgrades.
Kurt Binder focused on the financial mechanics: Q4 revenue of $94.4 million, full-year revenue of $365.9 million, gross margin of about 41%, and adjusted EBITDA of $52.4 million at a 14% margin. He noted free cash flow of $58.6 million, cash and marketable securities of $156 million, debt of $154.3 million, and operating cash flow of $66.9 million. He also flagged cost pressure from migrating SaaS applications to public cloud providers, higher G&A tied to legal and compliance work, the impact of ASC 606, and a $6.6 million non-cash tax charge plus a $2.4 million transition tax under the new tax law.
Analysts pressed on SaaS pipeline traction, especially the global freight transport customer, and management said that account is the largest element in the pipeline and could expand beyond the initial AssetOutlook deployment. They also asked about margins and the path to a 50% gross margin target; management said duplicate cloud-related costs should ease through the year, but LoJack’s legacy SVR mix is high-margin and the new LotSmart/SureDrive mix should be only modestly accretive. On LoJack, management said there is no fundamental change in outlook, but near-term channel revenue should not be expected to spike as the company prioritizes a longer-term recurring revenue model.
The call showed momentum in recurring revenue: deferred revenue rose 28% year over year, subscriber counts increased to about 730,000, and management pointed to multiple large SaaS wins still ramping. Core enterprise relationships also looked strong, with Caterpillar revenue up 53% for the year and management seeing room to expand penetration across SKUs. Management sounded confident that the LTE transition, new LoJack telematics offerings, and installed-base monetization can support longer-term growth and margin expansion.
Management explicitly warned that LoJack SVR-only revenue is in secular decline and that near-term U.S. dealer revenue could remain pressured as the brand transitions to telematics. Gross margin was only about 41%, and management said SaaS cloud migration costs and some unusual G&A/compliance expenses would continue to weigh on results in the near term. There was also acknowledged customer hesitation around LTE upgrades, which could create a temporary pause in device demand even if it eventually benefits sales.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.1%
- Shares Outstanding
- 62.75M
- Float Shares
- 38.36M
of shares held by institutions
62 13F filers
Buy/sell ratio 1.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jupiter Topco LLC | 6.31M | ▲ 6.31M |
| Janus Henderson Group Ltd. | 6.31M | 0 |
| 5am Venture Management, LLC | 5.87M | 0 |
| Vivo Capital, LLC | 5.58M | ▲ 1.34M |
| Fmr LLC | 4.91M | ▲ 4.52K |
| Stonepine Capital Management, LLC | 2.79M | ▲ 1.40M |
| Balyasny Asset Management L.P. | 2.58M | ▼ 56.71K |
| Vanguard Capital Management LLC | 2.15M | ▲ 612.81K |
| A16z Capital Management, L.L.C. | 2.13M | 0 |
| Blackrock, Inc. | 2.00M | ▲ 359.16K |
| Adage Capital Partners Gp, L.L.C. | 1.96M | 0 |
| Trails Edge Capital Partners, LP | 1.93M | ▼ 6.63K |
Held by 98 ETFs
Biggest fund positions in CAMP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 26 | Gold Kelly | buy | 10,000 |
| Aug 27, 26 | Schwab Andrew J. | sell | 400,000 |
| Aug 24, 26 | Schwab Andrew J. | sell | 10 |
| Aug 19, 26 | Schwab Andrew J. | sell | 45,147 |
| Aug 20, 26 | Schwab Andrew J. | sell | 114,700 |
| Aug 21, 26 | Schwab Andrew J. | sell | 32,018 |
| Aug 19, 26 | Tardiff Daniel | sell | 1,738 |
| Aug 3, 26 | 5AM Partners VI, LLC | buy | 3,179,558 |
| Aug 3, 26 | Schwab Andrew J. | other | 3,179,558 |
| Aug 3, 26 | Young Richard A | buy | 16,378 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CAMP coverage
Recent articles, reports, and earnings notes.
No research on CAMP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CAMP report →CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 17
CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data
marketbeat.com · Nov 11
CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears
marketbeat.com · Nov 9
CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 5
CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com · Nov 5
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
zacks.com · Oct 29
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
globenewswire.com · Oct 27
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
marketbeat.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.